01 / DESIGN
What was studied?
This open-label randomized trial compared tirzepatide with a specified semaglutide regimen in 1,879 people with type 2 diabetes over 40 weeks.
02 / FINDINGS
What did the researchers report?
Tirzepatide groups showed greater average reductions in glycated hemoglobin, the primary endpoint, and in body weight. Gastrointestinal adverse events occurred with both treatments.
03 / LIMITS
How should it be interpreted?
The study was open-label and did not compare every possible regimen. It is not a universal ranking of these molecules for every indication, and does not establish interchangeability of research materials with medicines.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.